- Home
- JRVR vs NMRA Comparison
JRVR vs NMRA Comparison
Compare JRVR & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRVR
- NMRA
- Stock Information
- Founded
- JRVR 2002
- NMRA 2019
- Country
- JRVR Bermuda
- NMRA United States
- Employees
- JRVR N/A
- NMRA N/A
- Industry
- JRVR Property-Casualty Insurers
- NMRA
- Sector
- JRVR Finance
- NMRA
- Exchange
- JRVR Nasdaq
- NMRA Nasdaq
- Market Cap
- JRVR 255.2M
- NMRA 268.5M
- IPO Year
- JRVR 2005
- NMRA 2023
- Fundamental
- Price
- JRVR $5.60
- NMRA $1.46
- Analyst Decision
- JRVR Buy
- NMRA Buy
- Analyst Count
- JRVR 4
- NMRA 8
- Target Price
- JRVR $6.06
- NMRA $7.14
- AVG Volume (30 Days)
- JRVR 179.2K
- NMRA 1.9M
- Earning Date
- JRVR 08-04-2025
- NMRA 08-06-2025
- Dividend Yield
- JRVR 0.70%
- NMRA N/A
- EPS Growth
- JRVR N/A
- NMRA N/A
- EPS
- JRVR N/A
- NMRA N/A
- Revenue
- JRVR $665,342,000.00
- NMRA N/A
- Revenue This Year
- JRVR $1.95
- NMRA N/A
- Revenue Next Year
- JRVR $6.80
- NMRA N/A
- P/E Ratio
- JRVR N/A
- NMRA N/A
- Revenue Growth
- JRVR N/A
- NMRA N/A
- 52 Week Low
- JRVR $3.00
- NMRA $0.61
- 52 Week High
- JRVR $7.80
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- JRVR 48.03
- NMRA 45.73
- Support Level
- JRVR $5.26
- NMRA $1.54
- Resistance Level
- JRVR $6.14
- NMRA $1.70
- Average True Range (ATR)
- JRVR 0.27
- NMRA 0.26
- MACD
- JRVR -0.01
- NMRA -0.09
- Stochastic Oscillator
- JRVR 38.64
- NMRA 2.11
About JRVR James River Group Holdings Ltd.
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.